Pseudohypoparathyroidism type I-b with neurological involvement is associated with a homozygous $\text{PTH1R}$ mutation

R. Guerreiro, J. Brás, S. Batista, P. Pires, M. H. Ribeiro, M. R. Almeida, C. Oliveira, J. Hardy and I. Santana

$^1$Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK, $^2$Department of Medical Sciences, Institute of Biomedicine – iBIMED, University of Aveiro, Aveiro, Portugal, $^3$Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, $^4$Hospital do Santo Espírito, Terceira, Portugal, $^5$CNC – Center for Neuroscience and Cell Biology, and $^6$Faculty of Medicine, University of Coimbra, Coimbra, Portugal

*Corresponding author: R. Guerreiro, Department of Molecular Neuroscience, UCL, Institute of Neurology, 1 Wakefield Street (1st Floor), London WC1N 1PJ, England. E-mail: r.guerreiro@ucl.ac.uk

**These authors contributed equally to this work.

Pseudohypoparathyroidism type 1b (PHP1b) is characterized by hypocalcemia, hyperphosphatemia, increased levels of circulating parathyroid hormone (PTH), and no skeletal or developmental abnormalities. The goal of this study was to perform a full characterization of a familial case of PHP1b with neurological involvement and to identify the genetic cause of disease. The initial laboratory profile of the proband showed severe hypocalcemia, hyperphosphatemia and normal levels of PTH, which was considered to be compatible with primary hypoparathyroidism. With disease progression the patient developed cognitive disturbance, PTH levels were found to be slightly elevated and a picture of PTH resistance syndrome seemed more probable. The diagnosis of PHP1b was established after the study of family members and blunted urinary cAMP results were obtained in a PTH stimulation test. Integration of whole genome genotyping and exome sequencing data supported this diagnosis by revealing a novel homozygous missense mutation in $\text{PTH1R}$ (p.Arg186His) completely segregating with the disease. Here, we demonstrate segregation of a novel mutation in $\text{PTH1R}$ with a phenotype of PHP1b presenting with neurological symptoms, but no bone defects. This case represents the extreme end of the spectrum of cognitive impairment in PTH dysfunction and defines a possible novel form of PHP1b resulting from the impaired interaction between PTH and $\text{PTH1R}$.

Keywords: Dementia, exome sequencing, Pseudohypoparathyroidism Type I-b, $\text{PTH1R}$

Received 10 February 2016, revised 1 May 2016, 10 May 2016, 1 June 2016, 4 July 2016, and 11 July 2016, accepted for publication 11 July 2016

Hypoparathyroidism (HP) and pseudohypoparathyroidism (PHP) are a group of heterogeneous conditions in which hypocalcemia and hyperphosphatemia occur as a result of deficient parathyroid hormone (PTH) secretion or end-organ PTH resistance (Thakker 2004). As a consequence of hypocalcemia, patients typically present with signs and symptoms of peripheral neuromuscular hyperexcitability (perioral numbness, paresthesias of the distal extremities or muscle cramping) that can progress to carpopedal spasm or tetany. Chronic HP and, more rarely, PHP are associated with central neurologic manifestations like epileptic seizures and extrapyramidal signs (Bhadada et al. 2011; Guberman & Jaworski 1979; Mitchell et al. 2012). The classical radiological finding is calcification of the basal ganglia (FAissol et al. 2008; Goswami et al. 2012; Kahloul et al. 2009) and encephalopathy (Gupta et al. 2011; Handa et al. 1995; Oechsner et al. 1996) or rapidly progressive dementia (Adorni et al. 2005; Mateo & Gimenez-Roldan 1982; Nicolai & Lazzarino 1994; Zambrana Garcia et al. 1998) have been described, but are usually responsive to treatment and rarely progressive (Stuvenenburg et al. 1996).

Hypoparathyroidism is mainly an acquired disease, characterized by low or inappropriately normal levels of PTH, resulting from damage or surgical excision of the parathyroid glands or autoimmune mechanisms. Genetic forms of HP are rare and usually associated with mutations in four genes: calcium-sensing receptor ($\text{CASR}$) (Bai et al. 1996; Pearce et al. 1996; Watanabe et al. 1998), glial cells missing homolog 2 ($\text{GCM2}$) (Ding et al. 2001), guanine nucleotide-binding protein alpha-11 ($\text{GNA11}$) (Mannstadt et al. 2013), and $\text{PTH}$ itself (Arnold et al. 1990; Parkinson & Thakker 1992; Sunthornthepvarakul et al. 1999).

Pseudohypoparathyroidism was first described by Fuller Albright et al. (1942) (Albright F., 1942) and the nomenclature used was based on the observation of renal resistance to PTH and increased levels of the hormone. Pseudohypoparathyroidism is divided into types I and II according to the absence or presence, respectively, of an increment in urinary cAMP excretion in response to exogenous PTH administration. PHP type 1 is further subdivided into PHP1a, PHP1b and...
et al. (Jan de Beur et al. 2000; Schipani et al. 1995b), and no linkage has been shown so far to the PTH1R locus in PHP1b families (Fukumoto et al. 1996, 1998). Given the complexities in the molecular, biochemical and physical features of PTH disorders, molecular testing is critical for achieving a clear diagnosis and validating the inheritance pattern in any given family. Nonetheless, the majority of familial cases of isolated HP and PHP remain unexplained most likely because adequate evaluation of known genes has not been undertaken, and because other genes must be involved in the molecular pathogenesis. Obvious potential candidate genes are the PTH receptor genes, nevertheless, to our knowledge; no mutations in these genes have been previously identified as causing these disorders. Here we report a Portuguese family with PHP type 1b with heterogeneous PTH levels and neurological manifestations, due to a novel PTH1R mutation.

Results

Clinical and laboratory findings in the index case

The index case is a Caucasian 68-year-old female, with the diagnosis of epilepsy at age 22, controlled with carbamazepine 800 mg/day. She had normal psychomotor development, no history of learning problems, and completed 6 years of education. Her past medical history was relevant for bilateral cataract with surgical extraction at the age 40, as well as a femur fracture at 44 years.

At 49 years old, complex partial seizures became recurrent and refractory to medication and she was first admitted to our inpatient unit for further investigation. Symptoms suggestive of tetany (mainly spasms of the inferior limbs) were present. On general physical examination she had no apparent dysmorphic features, brachidactyly, other deformities or subcutaneous calcifications. The bedside cognitive evaluation was unremarkable. Neurological examination revealed a slightly spastic ataxic gait, without cognitive impairment or other central nervous system (CNS) signs. In the diagnostic investigation, brain computed tomography (CT) scan showed multiple calcifications of basal ganglia and cerebellum (Fig. 2). Electrocardiogram (ECG) was normal, and electroencephalogram (EEG) revealed a generalized slowing and bilateral temporal paroxysmal activity, predominantly on the left side. Serum biochemical analysis presented severe hypocalcemia and hyperphosphatemia with normal proteins and renal function (Table 1). Parathyroid hormone levels were found to be within the normal range on successive evaluations. Thyroid function was normal and there were no other endocrine defects. The patient was at this time diagnosed with primary HP and started oral calcium supplementation with calcium carbonate 4 g/day and calcitriol 0.25 μg/day, in addition to maintenance of carbamazepine. Thereafter her physical condition improved with carbamazepine. Thereafter her physical condition

Methods

Genetic analyses

All studied individuals gave written informed consent for this study, which was approved by the University Hospital of Coimbra ethics committee and complies with the Declaration of Helsinki. In order to assess the presence of large structural variants and to perform homozygosity mapping, DNA samples from six siblings (II.1−II.6, Fig. 1) were run on Illumina’s HumanOmniExpress BeadChips as per manufacturer’s instructions (Illumina, San Diego, CA, USA). Data was visualized and analysed using the GenomeStudio Data Analysis Software (Illumina). After exclusion of molecular changes in GNAS by direct sequencing, Multiplex Ligation-dependent Probe Amplification (MLPA) and methylation tests in the index case, exome sequencing was performed in three siblings (II.1, II.2 and II.3, Fig. 1) with Illumina’s TruSeqExome Enrichment according to the manufacturer’s instructions. Sequencing was performed in Illumina’s HiSeq2000 using 100bp paired-end reads. Sanger sequencing was used to establish segregation of the mutation with disease status in all samples available for testing. Details for these analyses are given in the Supporting Information.

PTH stimulation test

A PTH stimulation test was performed in the index case using subcutaneous recombinant human PTH(1−34). In accordance with a protocol recently described (Todorova-Koteva et al. 2012), urinary cAMP and urinary phosphate were measured before PTH injection (baseline) and 2 and 4 h after the PTH challenge.
Mutation of PTH1R identified in family with PHP1b

Figure 2: Computed tomographic scan of the patient's brain. CT scans show extensive, bilateral calcification of dentate nuclei and cerebellar white matter (a), basal ganglia (b) and centrum semiovale and periventricular white matter (c).

normalized, seizures stopped and soon after hospital discharge she recovered her normal life and professional activity. Meanwhile, she was regularly followed at the endocrinology outpatient department, with dose adjustments of the calcium carbonate and calcitriol in accordance with serum calcium and phosphorus levels. In November 2009, at 66 years old, she developed an acute confusional state following an orthopaedic surgery, without complete recovery after discharge. Afterwards, the family noticed a progressive cognitive, although fluctuant, deterioration and functional decline in daily living activities. She was admitted to our inpatient department three months after the beginning of these symptoms. The neurological examination revealed moderate to severe cognitive deterioration (see Supporting Information for details). At this time, laboratory analyses revealed a mild hyperphosphatemia with normocalcaemia and a slight elevation of PTH levels (Table 1). Based on the blunt interval change in the urinary cAMP over time (Table 2), the patient was found to have resistance to PTH action and the diagnosis of PHP was assumed. Since mutations of GNAS are known to be associated with PTH resistance, the gene was tested at this time with negative results. Even though pharmacological intervention was tried, namely with in-care rigorous control and maintenance of normal serum calcium and phosphorus levels, through the careful adjustment of the calcium carbonate and calcitriol supplementation, the patient became bedridden, with hypokinetic rigidity, mutism and sporadic motor agitation and died after 2 years. Progression of clinical features, EEG and biochemical profile over time are summarized in Table 1.

Family history and investigation
A key feature of this case was the possible familial aggregation, pointing to a genetic form of disease. Family history evaluation and investigation revealed that the patient's parents were both from the same small village and a common ancestor was mentioned (Fig. 1). The patient's mother died of stroke in late life with no history of epilepsy, neurological or metabolic/bone disease. The father was always asymptomatic and refused laboratory or brain imaging, but consented to DNA sampling and analysis. He died 2 years after assessment, at 92 years of age without relevant symptoms. As is indicated in Fig. 1, the second generation included six siblings, 55 to 68 years old, of whom the index patient is the oldest. Subjects II.3, II.5 and II.6 were asymptomatic and with serum Ca, Ph and PTH levels within the normal range (Table 3). Subjects II.2 and II.4 both had the diagnosis of parathyroid dysfunction with cerebral calcification. Patient II.2 at the age of 50 experienced speech problems and, considering the neurological condition of her sister, requested laboratory investigation. Results were remarkable for hypocalcemia, hyperphosphatemia, high levels of PTH, normal thyroid function and cerebral calcifications. The diagnosis of PHP was proposed and the symptoms reverted with calcium carbonate and calcitriol. At the moment, with 67 years, she mentions subjective memory complaints but declined neuropsychological examination. Results were remarkable for hypocalcemia, hyperphosphatemia, high levels of PTH, normal thyroid function and cerebral calcifications. The diagnosis of PHP was proposed and the symptoms reverted with calcium carbonate and calcitriol. At the moment, with 67 years, she mentions subjective memory complaints but declined neuropsychological examination. A recent brain CT disclosed extensive calcifications of the basal ganglia, periventricular white matter, centrum semiovale and cerebellar white matter. Recent laboratory tests confirmed the high levels of PTH with normocalcemia/normophosphatemia and the presence of pallidal calcifications on brain CT (Table 3).

Genetic analyses
Homozygosity mapping in the six siblings revealed three large regions (>1 Mb) of loss of heterozygosity in chromosome 3.
Table 1: Clinical progression and correlation with calcaemia, phosphataemia, parathyroid hormone levels and electroencephalogram findings in the index case

| Date               | Age | PC seizures; Tetania | Confusional syndrome; Progressive cognitive deterioration | Recovery of motor and mental functions | Cognitive and motor worsening | Bedridden, with hypokinetic rigidity and mutism |
|--------------------|-----|----------------------|----------------------------------------------------------|----------------------------------------|-------------------------------|-----------------------------------------------|
| December 1992 (49 yo) |     |                      |                                                          |                                        |                               |                                               |
| February 2010 (66 yo) | 13/30 | None                |                                                          | 25/30                                  | 0/30 (Mutism)                 | 0/30 (Mutism)                                |
| August 2011 (67 yo)  | 8.4  |                      |                                                          | 3.8                                    |                               |                                               |
| November 2011 (68 yo) | 5.2  |                      |                                                          | 3.8                                    |                               |                                               |
| September 2012 (68 yo) | 74   |                      |                                                          | 4.0                                    |                               |                                               |

yo, years old (age of the patient at each evaluation); EEG, electroencephalogram; FIRDA, frontal intermittent rhythmic delta activity; PC, Partial Complex; PTH, Parathyroid hormone; Dec, December; Feb, February; Aug, August; Sept, September.

Table 2: Results of the parathyroid hormone stimulation test in the index case.

| Test                | Baseline | 2 h after PTH | 4 h after PTH |
|---------------------|----------|---------------|---------------|
| Urinary cAMP/Cr (nmol/mg) | 18.70    | 13.80         | 15.50         |
| Urinary PO4 (mmol/L)    | 3.8      | 13.5          | 8.8           |

cAMP, 3’5’ cyclic adenosine monophosphate; Cr, creatinine; PO4, phosphate; PTH, parathyroid hormone.

Discussion

Initially, the proband’s laboratorial presentation with severe hypocalcemia, hyperphosphatemia and normal levels of PTH was compatible with the diagnosis of primary HP. Later on, when she developed cognitive disturbance and PTH levels were slightly elevated, we were compelled to further investigate a PTH resistance syndrome. A PTH stimulation test was performed using subcutaneous recombinant human PTH-(1–34). The results of PTH infusion test in our patient were remarkable for a blunted urinary cAMP, which is typical for PTH resistance syndromes. The normal phosphaturic response observed may be considered atypical in this context, but a similar dissociated response has been described previously in patients with PHP (Kharb et al. 2011; Lewin et al. 1978; O’Neill et al. 1981; Stogmann & Fischer 1975). Some
explanations have been proposed, perhaps the more plausible one is that vitamin D supplementation normalizes the phosphaturic response (Kharb et al. 2011; Stogmann & Fischer 1975). An alternative hypothesis is that phosphaturic response to PTH may be independent of tubular adenylate cyclase stimulation in these patients (Stogmann & Fischer 1975). The integration of these results, with the high levels of PTH observed in other family members led us to propose the diagnosis of PHP. The further classification of PHP type 1b was based in the absence of bone malformation (osteodystrophy), as well as other endocrine defects, including normal thyroid function. We do not have an explanation for the unexpected normal PTH levels observed in our index case, which are divergent from the other two affected siblings and were possibly misleading. We can speculate whether this inability to increase PTH levels in response to a peripheral resistance is related to the severity of disease and especially to the inexorable evolution to dementia and akinetic mutism. In fact, PTH levels seem to modulate the severity of disease in all affected family members: subject II.4 has very high levels of PTH (365–500 pg/ml) and is asymptomatic; subject II.2 presents high PTH levels (172–198 pg/ml) and a mild phenotype (late onset cataracts and memory complaints); subject II.1 has mostly normal PTH levels and a severe cognitive deterioration. One other possible explanation, although highly unlikely, is the presence of two rare but very similar diseases in the same family. The unavailability of molecular data for GNAS in the affected siblings of the index case precludes the exclusion of this possibility (more details in Supporting Information).

Neurological involvement

The phenomenology and severity of the neurological involvement deserves some further comment. Delirium and cognitive decline are manifestations of HP and PHP, being usually associated and maybe pathophysiologically related to the presence of intracranial calcification (Adorni et al. 2005; Baptista et al. 1997; El Otmani et al. 2013; Kowdley et al. 1999; Nicolai & Lazzarino 1994; Roca et al. 1996). Hypocalcemia seems to be a key factor for calcifications as well as for common neurological symptoms like tetany, muscle cramping and seizures, which usually respond quickly to calcium replacement (Friedman et al. 1987; Fujita 2004). This was the case for our patient, where neuromuscular hyperexcitability and seizures were easily controlled and remained stable during disease progression. Cognitive deficits may also constitute transitory symptoms of acute hypocalcemia, usually integrating a more complex state of confusion and delirium, during episodes of status epilepticus or as a manifestation of encephalopathy with reversible brain edema (Gupta et al. 2011; Hossain 1970; Palmer et al. 1959). The profile of cognitive impairment initially presented by our patient also configures the definition of a confusional state or delirium related to metabolic encephalopathy (DSM IV, Association 1994). Hypocalcemia seems improbable according to the favourable evolution of other hypocalcemia-related symptoms and the apparent dissociation between symptoms and calcium/phosphate serum levels (Table 1). Moreover, the patient had no clinical or imagiological signs of brain edema, and epilepsy was controlled. There is at least one report of a reversible dementia-HP and consistent normocalcaemia with a rapid improvement and normalization of symptoms after therapy with 1,25-dihydroxy-cholecalciferol, suggesting that low levels of vitamin D could be a key factor (Stuerrenburg et al. 1996). However, our patient was on a stable dose of calcitriol (0.25 μg/day) since the beginning of symptoms, indicating that this is not a likely explanation in this case.

A review of the literature revealed that stable and severe cognitive deficits and dementia have been essentially associated to chronic HP and PHP and widespread intracranial calcifications (Baptista et al. 1997; Cartier et al. 2002; El Otmani et al. 2013; Modrego et al. 2005). Dementia appears late in the course of the disease in most cases, and it is characterized as a subcortical dementia, probably secondary to mineral deposits in subcortical structures, leading to disruption of frontostriatal circuits and dysfunction of inter-hemispheric relations (Cartier et al. 2002). Additionally, dementia, as well as hypokinesic rigidity, are considered late-stage manifestations of PH, and the least likely symptoms to respond to therapy (Friedman et al. 1987). Our patient also configures this type of sub-cortical frontal dementia, but with a more rapid and aggressive profile, and is paradigmatic of these overlapping syndromes, which may also indicate the existence of

---

**Table 3:** Biochemical and imagiological characteristics of the family members (affected members are under treatment)

|                | II-1 (index patient) | II-2 | II-3 | II-4 | II-5 | II-6 |
|----------------|----------------------|------|------|------|------|------|
| Calcemia (8.4–10.2 mg/dl) | 8.5 | 8.7 | 9.4 | 8.6 | 9.3 | 8.4 |
| Phosphatemia (2.5–4.5 mg/dl) | 4.0 | 3.6 | 3.8 | 3.5 | 3.1 | 2.9 |
| PTH (10–70 pg/ml) | 35–74 | 172–198 | 53.7 | 365–500 | 47 | 31 |
| TSH (0.27–4.20 mUI/L) | 1.5 | 1.8 | 0.94 | 2.3 | 2.1 | 0.83 |
| Cranial CT scan | Multiple calcifications | Multiple calcifications | N | Pallidal calcifications | N | N |
| Medication | Calcium carbonate + calcitriol | Calcium carbonate + calcitriol | – | Calcium carbonate + calcitriol | – | – |

The identifications for family members relate to Fig. 1. N, normal; –, no medication.

**Table 4:** Regions of extended homozygosity (>1 Mb) shared by affected and absent in unaffected siblings

| Chromosome | Start (bp) | End (bp) | Size (bp) |
|------------|------------|----------|-----------|
| 3          | 50,039,030 | 51,137,089 | 1,097,056 |
| 3          | 88,327,613 | 90,194,622 | 1,867,009 |
| 3          | 155,929,451 | 165,555,125 | 9,625,674 |

Start and End refer to the positions in chromosome 3, hg19.
and extensive brain calcifications. The clinical phenomenology of her sister was similar, presenting essentially with cognitive symptoms less symptomatic, but the clinical phenomenology of her sister was characterized by advanced endochondral bone maturation, and with Eiken syndrome, presenting with skeletal features contrasting to the Blomstrand’s phenotype and mainly characterized by retarded ossification (Duchatelet et al. 2005). Heterozygous mutations have been associated with primary failure tooth eruption and with Jansen’s metaphyseal chondrodysplasia (a rare form of dwarfishism associated with hypercalcemia) (Decker et al. 2008; Schipani et al. 1995a). Additionally, germline and somatic mutations have been associated with Ollier disease (a type of enchondromatosis) (Hopyan et al. 2002), although this association is still to be confirmed (Rozeman et al. 2004). Table S2 summarizes the different types of mutations previously associated with these diseases. Here, we associate a novel homozygous missense mutation in PTH1R with PHP1b. The mutation, located in residue 186 of the protein, is predicted to be pathogenic by different prediction software and this residue, located just at the N-terminal extracellular/transmembrane-1 junction, has previously been shown to be essential for contact with position 13 of PTH (Adams et al. 1998). The proband in this family presents no symptoms of either Blomstrand's chondrodysplasia or Eiken syndrome and no family members reported delayed tooth eruption. This indicates that the location of the change in the protein is probably relevant for the downstream associated phenotype. The interaction between PTH and PTH1R has been predicted as a two-site general interaction model involving two main components: (1) an interaction between the C-terminal domain of the ligand and the N-terminal domain of the receptor – mainly contributing to binding affinity; and (2) an interaction between the N-terminal portion of the ligand and the juxtamembrane region of the receptor – contributing to signalling (Cardella & Juppner 2001). More specifically, point mutations at the neighbouring hydrophobic residues Phe184, Leu187 and Ile190 were shown to impair the interaction with PTH(3–34) and PTH(1–14) with a PTH(1–34) analog possibly crosslinking to PTH1R at Arg186 (Carter et al. 1999). The late onset of disease in this family is in accordance with the conclusion that the effect of two different mutations (p.Arg186Lys and p.Arg186Ala) engineered in the same residue as the mutation here described, is local and does not involve global conformational changes of the receptor. As such, this novel mutation (p.Arg186His) is expected to diminish the binding affinity and ligand specificity of the receptor, rather than abolish the overall function of PTH1R (Adams et al. 1998). In fact, a very similar phenotype to the one observed in this family has recently been reported to be associated with a novel homozygous mutation in PTH. The five previously known PTH mutations were all located in exon 2 of the gene that encodes the pre-pro leader sequence of the hormone. All these mutations lead to inadequate secretion of the mature PTH(1–84) polypeptide. The novel PTH mutation (p.Arg25Cys) identified by Lee et al. is the first located within the α-helical portion of PTH that mediates critical binding interactions with PTH1R and was shown to impair the PTH/PTH1R activation (Lee et al. 2015). The mutation we identified in PTH1R is expected to have a similar effect in this ligand-receptor complex, possibly defining a novel form of PHP1b resulting from the impaired interaction between PTH and PTH1R.

In summary, the index case reported here represents the extreme end of the spectrum of cognitive impairment in PTH

### Table 5: Bioinformatics analysis of whole-exome sequencing in the studied family

| Filter step                                                                 | Individuals |
|----------------------------------------------------------------------------|-------------|
| Variants in coding regions or at splice sites                               | II.1        | II.2        | II.3        |
| and homozygous                                                             | 18205       | 18044       | 17220       |
| and not in dbSNP 132, 1000Genomes or control exomes                        | 7832        | 7788        | 8140        |
| and changes aminoacid or splice site                                        | 24          | 23          | 25          |
| and shared between affected and absent from unaffected siblings             | 20          | 16          | 16          |
| and located within shared homozygosity regions                              | 1 (PTH1R:p.Arg186His) |

Filtering pipeline applied to the studied family whole-exome sequencing data.

common pathological mechanisms subjacent to delirium and dementia. The mechanism of calcium deposition is not clear, but according to others may be due to chronic abnormalities of intra- and extracellular concentrations of calcium and phosphate (Fujita 2004; Goswami et al. 2012). Proposed mechanisms of extrapyramidal dysfunction and maybe dementia include altered vessel permeability to calcium and tissue ischaemia, abnormal synaptic excitability and ephaptic transmission, or local shifts in calcium concentration, possibly mediated by altered activity of the cerebral isoform of PTH responsive adenyl cyclase (Warren et al. 2002). In our opinion there were no other co-morbidities in our patient to explain this dementia end-stage. In fact, all forms of treatable dementia were excluded and there were no biomarkers of degenerative dementia, namely Alzheimer’s disease. Besides, the observed clinical profile, with a fluctuating encephalopathy rapidly evolving to dementia with extrapyramidal features and finally to hypokinetic rigidity and mutism is atypical for degenerative dementias. The other affected family members are less symptomatic, but the clinical phenomenology of her sister is similar, presenting essentially with cognitive symptoms and extensive brain calcifications.

### PTH1R mutations

Mutations in PTH1R have previously been associated with five different diseases, reflecting the wide range of functions and pathways in which this receptor is involved. Homozygous mutations have been associated with Blomstrand’s chondrodysplasia, a human embryonic lethal disorder characterized by advanced endochondral bone maturation, and with Eiken syndrome, presenting with skeletal features contrasting to the Blomstrand’s phenotype and mainly characterized by slowed ossification (Duchatelet et al. 2005). Heterozygous mutations have been associated with primary failure tooth eruption and with Jansen’s metaphyseal chondrodysplasia (a rare form of dwarfishism associated with hypercalcemia) (Decker et al. 2008; Schipani et al. 1995a). Additionally, germline and somatic mutations have been associated with Ollier disease (a type of enchondromatosis) (Hopyan et al. 2002), although this association is still to be confirmed (Rozeman et al. 2004). Table S2 summarizes the different types of mutations previously associated with these diseases. Here, we associate a novel homozygous missense mutation in PTH1R with PHP1b. The mutation, located in residue 186 of the protein, is predicted to be pathogenic by different prediction software and this residue, located just at the N-terminal extracellular/transmembrane-1 junction, has previously been shown to be essential for contact with position 13 of PTH (Adams et al. 1998). The proband in this family presents no symptoms of either Blomstrand’s chondrodysplasia or Eiken syndrome and no family members reported delayed tooth eruption. This indicates that the location of the change in the protein is probably relevant for the downstream associated phenotype. The interaction between PTH and PTH1R has been predicted as a two-site general interaction model involving two main components: (1) an interaction between the C-terminal domain of the ligand and the N-terminal domain of the receptor – mainly contributing to binding affinity; and (2) an interaction between the N-terminal portion of the ligand and the juxtamembrane region of the receptor – contributing to signalling (Cardella & Juppner 2001). More specifically, point mutations at the neighbouring hydrophobic residues Phe184, Leu187 and Ile190 were shown to impair the interaction with PTH(3–34) and PTH(1–14) with a PTH(1–34) analog possibly crosslinking to PTH1R at Arg186 (Carter et al. 1999). The late onset of disease in this family is in accordance with the conclusion that the effect of two different mutations (p.Arg186Lys and p.Arg186Ala) engineered in the same residue as the mutation here described, is local and does not involve global conformational changes of the receptor. As such, this novel mutation (p.Arg186His) is expected to diminish the binding affinity and ligand specificity of the receptor, rather than abolish the overall function of PTH1R (Adams et al. 1998). In fact, a very similar phenotype to the one observed in this family has recently been reported to be associated with a novel homozygous mutation in PTH. The five previously known PTH mutations were all located in exon 2 of the gene that encodes the pre-pro leader sequence of the hormone. All these mutations lead to inadequate secretion of the mature PTH(1–84) polypeptide. The novel PTH mutation (p.Arg25Cys) identified by Lee et al. is the first located within the α-helical portion of PTH that mediates critical binding interactions with PTH1R and was shown to impair the PTH/PTH1R activation (Lee et al. 2015). The mutation we identified in PTH1R is expected to have a similar effect in this ligand-receptor complex, possibly defining a novel form of PHP1b resulting from the impaired interaction between PTH and PTH1R.

In summary, the index case reported here represents the extreme end of the spectrum of cognitive impairment in PTH
Mutation of PTH1R identified in family with PHP1b

Figure 3: Identification of the homozygous p.Arg186His mutation in PTH1R. The top panel shows the region on chromosome 3 where PTH1R is located, with the coverage obtained from exome sequencing for each exon of the gene and both transcripts represented. The medium panel represents the variant calling obtained from exome sequencing at the p.Arg186His locus for one affected sibling, on the left, and Sanger sequencing traces for one affected and two unaffected samples from the family, on the right. The first sequence on the top corresponds to an affected individual (homozygous ‘AA’ at the p.Arg186His position), while the two bottom sequences show unaffected individuals (one homozygous wild-type ‘GG’ and one heterozygous ‘GA’). The bottom panel shows the protein sequence comparison displaying high conservation across species: NP_001107740.1: M. musculus; NP_064458.1: R. norvegicus; NP_001068800.1: B. taurus; NP_001003155.1: C. lupus; XP_001113857.1: M. mulatta; NP_000307.1: H. sapiens; XP_001152178.1: P. troglodytes; NP_00117046.1: G. gallus; NP_571432.1: D. rerio.
dysfunction and is a dramatic example of refractoriness to treatment. Considering that this is also the first family identified to have PHP1b due to a mutation in PTH1R, we can speculate that this cognitive profile is the phenotype of this mutation. Furthermore, the resistance to PTH may be explained by an abnormal interaction between PTH and the PTH1R receptor, eventually modulated by a compensatory-elevation of PTH. These are potentially interesting mechanisms to explore further with functional analyses.

References

Adams, A.E., Bisello, A., Chorev, M., Rosenblatt, M. & Suva, L.J. (1994) Arginine 186 in the extracellular N-terminal region of the human parathyroid hormone 1 receptor is essential for contact with position 13 of the hormone. Mol Endocrinol 12, 1673–1683.

Adorni, A., Lussignoli, G., Geroldi, C. & Zanetti, O. (200) Extensive brain calcification and dementia in postsurgical hypoparathyroidism. Neurology 65, 1501.

Albright, F.B.C., Smith, Ph & Parson, W. (1942) Pseudohypoparathyroidism – an example of “Seabright-Bantam Syndrome. Endocrinology 30, 922–932.

Arnold, A., Horst, S.A., Gardella, T.J., BABA, H., ARNOLD, A., HORST, S.A., GARDELLA, T.J., BABA, H., ARNOLD, A., HORST, S.A., GARDELLA, T.J., BABA, H., ARNOLD, A., HORST, S.A., GARDELLA, T.J., BABA, H., ARNOLD, A., HORST, S.A., GARDELLA, T.J., BABA, H., ARNOLD, A., HORST, S.A., GARDELLA, T.J., BABA, H., ARNOLD, A., HORST, S.A., GARDELLA, T.J., BABA, H., ARNOLD, A., HORST, S.A., GARDELLA, T.J.

Bai, M., Quinn, S., Trivedi, S., Kifor, O., Pearce, S.H., Pollak, M.R., Arnold, A., Horst, S.A., Gardella, T.J., Baba, H., Levine, M.A. & Bhadada, S.K., Bhansali, A., Upreti, V., Subbiah, S. & Khandelwal, Baptista, M.V., Vale, J. & Leitao, O. (1997) Striato-pallido-dentate dysfunction and is a dramatic example of refractivity to treatment. Clin Calcium 14, 55–57.

Fukumoto, S., Suzawa, M., Takeuchi, Y., Kodama, Y., Nakayama, K., OGATA, E., MATSUMOTO, T. & FUJITA, T. (1996) Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab 81, 2554–2556.

Fukumoto, S., Suzawa, M., Kikuchi, T., Matsumoto, T., Kato, S. & Fujita, T. (1998) Cloning and characterization of kidney-specific promoter of human PTH/PTHrP receptor gene: absence of mutation in patients with pseudohypoparathyroidism type Ib. Mol Cell Endocrinol 141, 41–47.

Gardella, T.J. & Juppner, H. (2001) Molecular properties of the PTH/PTHrP receptor. Trends Endocrinol Metab 12, 210–217.

Goswami, R., Sharma, R., Sreenivas, V., Gupta, N., Ganapathy, A. & Das, S. (2012) Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf) 77, 200–206.

Guberman, A. & Javorski, Z.F. (1979) Pseudohypoparathyroidism and epilepsy: diagnostic value of computerized cranial tomography. Epilepsia 20, 541–553.

Gupta, M., Lehl, S.S. & Sachdev, A. (2011) Idiopathic hypoparathyroidism – an unusual cause of acute encephalopathy. BMJ Case Rep 2011: 10.1136/bcr.2010.3593, 24 March 2011.

Handa, R., Wali, J.P., Singh, R.I. & Aggarwal, P. (1995) Corticosteroids precipitating hypocalcemic encephalopathy in hypoparathyroidism. Ann Emerg Med 26, 241–242.

Hopyan, S., Gokgoz, N., Poon, R., Gensre, C.R., Yu, C., Cole, W.G., Bell, R.S., Juppner, H., Andrusi, I.L., Wunder, J.S. & Alman, B.A. (2002) A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet 30, 306–310.

Hossain, M. (1970) Neurological and psychiatric manifestations in idiopathic hypoparathyroidism: response to treatment. J Neurol Neurosurg Psychiatry 33, 153–156.

Jan de Beur, S.M., Ding, C.L., LaBuda, M.C., Usdin, T.B. & Levine, M.A. (2000) Pseudohypoparathyroidism 1b: exclusion of parathyroid hormone and its receptors as candidate disease genes. J Clin Endocrinol Metab 85, 2239–2246.

Kahloul, N., Chauri, V., Boughamoura, L., Charfeddine, L., Khammari, S. & Amri, F. (2009) Pseudohypoparathyroidism: an unusual cause of acute encephalopathy. Ann Emerg Med 26, 241–242.

Kahlow, B., Lehl, S.S. & Sachdev, A. (2011) Idiopathic hypoparathyroidism – an unusual cause of acute encephalopathy. BMJ Case Rep 2011: 10.1136/bcr.2010.3593, 24 March 2011.

Kharb, S., Gundurthi, A., Datta, M.K. & Garg, M.K. (2011) Adult onset pseudohypoparathyroidism type-1b with normal phosphaturic response to exogenous parathyroid hormone. Indian J Endocrinol Metab 15, 337–340.

Kowdley, K.V., Couill, B.M. & Orrwell, E.S. (1999) Cognitive impairment and intracranial calcification in chronic hypoparathyroidism. Am J Med Sci 317, 273–277.

Lee, S., Mannstadt, M., Guo, J., Kim, S.M., Yi, H.S., Khatri, A., Dean, T., Okazaki, M., Gardella, T.J. & Juppner, H. (2015) A Homozygous [Cys255]PTH1–84 mutation that impairs PTH/PTHrP receptor activation defines a novel form of hypoparathyroidism. J Bone Miner Res 30, 1803–1813.

Lewin, I.G., Papapoulos, S.E., Tomlinson, S., Hendy, G.N. & O’Riordan, J.L. (1978) Studies of hypoparathyroidism and pseudo-hypoparathyroidism. Q J Med 47, 533–548.

Mannstadt, M., Harris, M., Bravenboer, B., Chitturi, S., Dreijerink, K.M., Lambrick, D.G., Lim, E.T., Daly, M.J., Gabriel, S. & Juppner, H. (2013) Germine mutations affecting Galphai1 in hypoparathyroidism. N Engl J Med 368, 2523–2534.

Mateo, D. & Gimenez-Roldan, S. (1982) Dementia in idiopathic hypoparathyroidism. Rev Med QJM 53, 541–553.

Mehlig, M., Regan, S., Cooley, M.R., Lauter, K.B., Vrla, M.C., Beckner, C.B., Burnett-Bovine, S.A. & Mannstadt, M. (2012) Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97, 4507–4514.

Friedman, J.H., Chiu, C., & Tucci, J.R. (1987) Idiopathic hypoparathyroidism with extensive brain calcification and persistent neurologic dysfunction. Neurology 37, 307–309.

Juppner, H. (2004) Mechanism of intracerebral calcification in hypoparathyroidism. Clin Calcium 14, 55–57.

Krapcho, K., Hebert, S.C. & Brown, E.M. (1996) Expression of intracerebral calcification and dementia in postsurgical hypoparathyroidism. Am J Hum Genet 83, 424–425.

Mitchell, D.M., Regan, S., Cooley, M.R., Lauter, K.B., Vrla, M.C., Beckner, C.B., Burnett-Bovine, S.A. & Mannstadt, M. (2012) Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97, 4507–4514.
Mutation of PTH1R identified in family with PHP1b

Warren, J.D., Mummerly, C.J., Al-Din, A.S., Brown, P. & Wood, N.W. (2002) Corticobasal degeneration syndrome with basal ganglia calcification: Fahr’s disease as a corticobasal look-alike? Mov Disord 17, 563–567.

Watanabe, T., Bai, M., Lane, C.R., Matsumoto, S., Minamitani, K., Minagawa, M., Niimi, H., Brown, E.M. & Yasuda, T. (1998) Familial hypoparathyroidism: identification of a novel gain of function mutation in transmembrane domain 5 of the calcium-sensing receptor. J Clin Endocrinol Metab 83, 2497–2502.

Zambrana Garcia, J.L., Delgado Fernandez, M., Laynez Bretones, F. & Diez Garcia, F. (1998) Dementia as the first manifestation of idiopathic hypoparathyroidism. Med Clin (Barc) 110, 478.

Acknowledgments

The authors would like to thank the family members that participated in this study. The authors would also like to thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison. A full list of contributing groups can be found at http://exac.broadinstitute.org/about. This work was supported in part by an anonymous donor, the Alzheimer’s Research UK, the Wellcome Trust/Medical Research Council Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson’s Disease Consortium (members are from the University College London Institute of Neurology, the University of Sheffield and the Medical Research Council Protein Phosphorylation Unit at the University of Dundee), and fellowships from the Alzheimer’s Society to J.B. and R.G. The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. The authors have no conflicts of interest.

Supporting Information

Additional supporting information may be found in the online version of this article at the publisher’s web-site:

Appendix S1: Methods.

Figure S1: Homozygosity analysis. The left panel represents the large tracts of homozygosity shared between affected and absent in unaffected siblings across the entire genome and depicted as blue bars over the corresponding chromosome. Only three regions >1 Mb segregate with the disease in this family. The right panel shows the results for chromosome 3 from whole genome genotyping represented by the log ratio in the bottom and B allele frequencies for each of the six siblings. The pink vertical line indicates the location of PTH1R in chromosome 3. All affected siblings have large homozygous regions encompassing PTH1R while unaffected siblings show heterozygosity in the same loci.

Figure S2: Bone X-ray of the proband. Bone X-ray showing generalized osteopenia, but without skeletal abnormalities suggestive of Albright’s hereditary osteodystrophy, Blomstrand’s chondrodysplasia, Eiken skeletal dysplasia or Murk Jansen type of metaphyseal chondrodysplasia.

Figure S3: Cerebral SPECT of the index case. Cerebral SPECT disclosed cerebral hyperperfusion mainly at the frontal regions and basal ganglia, predominantly on the left side.

Modrego, P.J., Mojonero, J., Serrano, M. & Fayad, N. (2005) Fahr’s syndrome presenting with pure and progressive presenile dementia. Neural Sci 26, 367–369.

Nicola, A. & Lazzerini, L.G. (1994) Dementia syndrome in patients with post-surgical hypoparathyroidism and extensive brain calcifications. Eur Neurol 34, 230–235.

Oechsner, M., Pfeiffer, G., Timmermann, K., Kromer, H., Sturenburg, H.J. & Kunze, K. (1996) Acute reversible encephalopathy with brain edema and serial seizures in pseudohypoparathyroidism. Nervenarzt 67, 875–879.

O’Neill, S., Walker, F. & O’Dwyer, W.F. (1981) Pseudohypoparathyroidism: identification of a novel gain of function mutation in transmembrane domain 5 of the calcium-sensing receptor. J Clin Endocrinol Metab 83, 2497–2502.

Palmer, R.F., Searles, H.H. & Boldrey, E.B. (1959) Papilloedema with postsurgical hypoparathyroidism and extensive brain calcification: Fahr’s disease as a corticobasal look-alike? Mov Disord 17, 563–567.

Parkinson, D.B. & Thakker, R.V. (1992) A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism. Nat Genet 1, 149–152.

Pearce, S.H., Williamson, C., Kifor, O., Bai, M., Coulthard, M.G., Davies, M., Lewis-Barned, N., McCredie, D., Powell, H., Kendall-Taylor, P., Brown, E.M. & Thakker, R.V. (1996) A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335, 1115–1122.

Roca, B., Minguéz, C., Saez-Royuela, A. & Simon, E. (1995) Dementia, myopathy, and idiopathic hypoparathyroidism. Postgrad Med J 71, 702.

Rozeman, L.B., Sangiorgi, L., Briare-de Bruin, I.H., Mainil-Varlet, P., Bertoni, F., Cleton-Jansen, A.M., Hogendoorn, P.C. & Bovee, J.V. (2004) Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTH1R mutation p.R150C. Hum Mutat 24, 466–473.

Schipani, E., Kruse, K. & Juppner, H. (1995a) A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268, 98–100.

Schipani, E., Weinstein, L.S., Bergwitz, C., Ida-Klein, A., Kong, X.F., Stuhmann, M., Kruse, K., Whyte, M.P., Murray, T., Schmidtke, J. et al. (1995b) Pseudohypoparathyroidism type Ib is not caused by mutations in the coding exons of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene. J Clin Endocrinol Metab 80, 1611–1621.

Stogmann, W. & Fischer, J.A. (1975) Pseudohypoparathyroidism. Disappearance of the resistance to parathyroid extract during treatment with vitamin D. Am J Med 59, 140–144.

Sturenburg, H.J., Hansen, H.C., Thie, A. & Kunze, K. (1996) Reversible dementia in idiopathic hypoparathyroidism associated with normocalcemia. Neurology 47, 474–476.

Sunthornthevpavarakul, T., Churessigaw, S. & Ngowngarmratana, S. (1999) A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism. J Clin Endocrinol Metab 84, 3792–3796.

Thakker, R.V. (2004) Genetics of endocrine and metabolic disorders: parathyroid. Rev Endocr Metab Disord 5, 37–51.

Thiele, S., de Sanctis, L., Werner, R., Grotzinger, J., Aydin, C., Juppner, H., Bastepe, M. & Hiort, O. (2011) Functional characterization of GNAS mutations found in patients with pseudohypoparathyroidism type Ic defines a new subgroup of pseudohypoparathyroidism affecting selectively Gsalpha-receptor interaction. Hum Mutat 32, 653–660.

Todorova-Koteva, K., Wood, K., Imam, S. & Jaume, J.C. (2012) Screening for parathyroid hormone resistance in patients with non-phenotypically evident pseudohypoparathyroidism. Endocr Pract 18, 864–869.